top of page

SynaptixBio launched with singular focus

Updated: Dec 16, 2021

A new biotech company has been launched with the goal of taking on one of the world’s rarest neurodegenerative…

To continue reading please go to the article on The Pharma Letter

21 views0 comments

Recent Posts

See All

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst

bottom of page